[go: up one dir, main page]

BR9814912A - Sequência genÈmica e polipeptìdeos de chlamydia trachomatis, fragmentos dos mesmos e usos dos mesmos, em particular para o diagnóstico, a prevenção e o tratamento de infecção - Google Patents

Sequência genÈmica e polipeptìdeos de chlamydia trachomatis, fragmentos dos mesmos e usos dos mesmos, em particular para o diagnóstico, a prevenção e o tratamento de infecção

Info

Publication number
BR9814912A
BR9814912A BR9814912-1A BR9814912A BR9814912A BR 9814912 A BR9814912 A BR 9814912A BR 9814912 A BR9814912 A BR 9814912A BR 9814912 A BR9814912 A BR 9814912A
Authority
BR
Brazil
Prior art keywords
polypeptides
chlamydia trachomatis
infection
prevention
treatment
Prior art date
Application number
BR9814912-1A
Other languages
English (en)
Inventor
Reny Griffais
Susan K Hoiseth
Robert J Zagursky
Benjamin J Metcalf
Joel A Peek
Banumathi Sankaran
Leah D Fletcher
Original Assignee
Genset Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset Sa filed Critical Genset Sa
Publication of BR9814912A publication Critical patent/BR9814912A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: <B>"SEQuêNCIA GENÈMICA E POLIPEPTìDEOS DE CHLAMYDIA TRACHOMATIS, FRAGMENTOS DOS MESMOS E USOS DOS MESMOS, EM PARTICULAR PARA O DIAGNóSTICO, A PREVENçãO E O TRATAMENTO DE INFECçãO"<D>. O assunto da invenção é a seq³ência genómica e as seq³ências de nucleotídeo que codificam polipeptídeos de Chlamydia trachomatis, tais como polipeptídeos de envoltório celular, que são secretados ou específicos, ou que estão envolvidos no metabolismo, no processo de replicação ou na virulência, polipeptídeos codificados por tais seq³ências, assim como vetores que incluem as ditas seq³ências e células ou animais transformados com estes vetores. A invenção também refere-se a produtos de gene transcripcional do genoma de Chlamydia trachomatis, tais como, por exemplo, moléculas anti-sentido e de ribosima, que podem ser usados para controlar o crescimento do microorganismo. A invenção também refere-se a processos para detectar estes ácidos nucléicos ou polipeptídeos e kits para diagnosticar infecção por Chlamydia trachomatis. A invenção também refere-se a um processo para selecionar compostos capazes de modular infecção bacteriana e um processo para a biossíntese ou a biodegradação de moléculas de interesse usando as ditas seq³ências de nucleotídeo ou os ditos polipeptídeos. A invenção finalmente compreende composições farmacêuticas, em particular vacina, para a prevenção e/ou o tratamento de infecções bacterianas, em particular Chlamydia trachomatis.
BR9814912-1A 1997-11-28 1998-11-27 Sequência genÈmica e polipeptìdeos de chlamydia trachomatis, fragmentos dos mesmos e usos dos mesmos, em particular para o diagnóstico, a prevenção e o tratamento de infecção BR9814912A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9715041 1997-11-28
FR9716034 1997-12-17
US10707798P 1998-11-04 1998-11-04
PCT/IB1998/001939 WO1999028475A2 (en) 1997-11-28 1998-11-27 Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection

Publications (1)

Publication Number Publication Date
BR9814912A true BR9814912A (pt) 2000-10-03

Family

ID=27253391

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814912-1A BR9814912A (pt) 1997-11-28 1998-11-27 Sequência genÈmica e polipeptìdeos de chlamydia trachomatis, fragmentos dos mesmos e usos dos mesmos, em particular para o diagnóstico, a prevenção e o tratamento de infecção

Country Status (8)

Country Link
EP (6) EP2228385A1 (pt)
JP (2) JP2002517179A (pt)
KR (6) KR100735653B1 (pt)
CN (1) CN1280619A (pt)
AU (1) AU754264B2 (pt)
BR (1) BR9814912A (pt)
CA (1) CA2309228A1 (pt)
WO (1) WO1999028475A2 (pt)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
US5858720A (en) * 1997-07-23 1999-01-12 Smithkline Beecham Corporation Hiss
US5882892A (en) 1997-07-23 1999-03-16 Smithkline Beecham Corporation Asps
US6001602A (en) 1997-07-23 1999-12-14 Smithkline Beecham Corporation DNA encoding Chlamydia trachomatis isoleucyl tRNA synthetase polypeptides
US5962666A (en) * 1997-09-16 1999-10-05 Smithkline Beecham Corporation Deformylase
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
AU754122B2 (en) * 1998-04-20 2002-11-07 State of Oregon, acting by and through The State Board Of Higher Education, on behalf of Oregon State University, The Chlamydia proteins and their uses
WO2000011180A1 (en) 1998-08-20 2000-03-02 Connaught Laboratories Limited NUCLEIC ACID MOLECULES ENCODING POMP91A PROTEIN OF $i(CHLAMYDIA)
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
AU5366099A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
US6649370B1 (en) 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
EP1135501A1 (en) 1998-12-01 2001-09-26 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6555115B1 (en) 1998-12-08 2003-04-29 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
HUP0400719A3 (en) * 1998-12-08 2010-08-30 Corixa Corp Compounds and methods for treatment and diagnosis of chlamydial infection
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US6447779B1 (en) 1998-12-08 2002-09-10 Corixa Corporation Compounds for the diagnosis of Chlamydial infection
US6448234B1 (en) * 1998-12-08 2002-09-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6432916B1 (en) 1998-12-08 2002-08-13 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
JP2002541766A (ja) 1998-12-28 2002-12-10 アベンティス、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
NZ514140A (en) 1999-03-12 2001-09-28 Aventis Pasteur Chlamydia antigens and corresponding DNA fragments and uses thereof
JP4695763B2 (ja) 1999-05-03 2011-06-08 サノフィ、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
US7179638B2 (en) 1999-07-30 2007-02-20 Large Scale Biology Corporation Microarrays and their manufacture by slicing
US6713309B1 (en) 1999-07-30 2004-03-30 Large Scale Proteomics Corporation Microarrays and their manufacture
GB9917975D0 (en) * 1999-07-30 1999-09-29 Smithkline Beecham Biolog Novel compounds
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
AU7398300A (en) * 1999-09-17 2001-04-24 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
CA2385325C (en) 1999-09-20 2012-04-10 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
AU1481001A (en) * 1999-11-19 2001-05-30 Michigan State University Recombinant chlamydia vaccine
EP1240331B1 (en) 1999-12-22 2010-04-07 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
EP1114867A1 (en) * 1999-12-27 2001-07-11 Universite De Geneve Transcription regulatory sequences derived from Chlamydomonas reinhardtii
US6316211B1 (en) 2000-01-26 2001-11-13 Smithkline Beecham Corporation ThdF
US20010048927A1 (en) 2000-02-01 2001-12-06 Richard Stephens Porin B (PorB) as a therapeutic target for prevention and treatment of infection by chlamydia
US20020132994A1 (en) * 2000-04-04 2002-09-19 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
DE60133190T2 (de) 2000-04-21 2009-04-02 CORIXA CORP., Wilmington Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
US6919187B2 (en) 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
EP1283909A4 (en) * 2000-05-04 2006-06-07 Univ Yale HIGH DENSITY PROTEIN ARRAYS FOR SCREENING PROTEIN ACTIVITY
EP2166019A3 (en) 2000-07-03 2010-06-09 Novartis Vaccines and Diagnostics S.r.l. Immunisation against Chlamydia Pneumoniae
US7811592B2 (en) 2000-08-16 2010-10-12 Auburn University Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of Chlamydia
AUPQ954000A0 (en) * 2000-08-18 2000-09-14 Queensland University Of Technology Novel diagnostic agents and uses therefor
US6539102B1 (en) 2000-09-01 2003-03-25 Large Scale Proteomics Reference database
US6980674B2 (en) 2000-09-01 2005-12-27 Large Scale Proteomics Corp. Reference database
US7537772B1 (en) * 2000-10-02 2009-05-26 Emergent Product Development Gaithersburg Inc. Chlamydia protein, gene sequence and the uses thereof
US7731980B2 (en) 2000-10-02 2010-06-08 Emergent Product Development Gaithersburg Inc. Chlamydia PMP proteins, gene sequences and uses thereof
EP1671981A3 (en) 2000-10-27 2006-07-05 Chiron SRL. Nucleic acids and proteins from streptococcus group A
US6682889B1 (en) 2000-11-08 2004-01-27 Becton, Dickinson And Company Amplification and detection of organisms of the Chlamydiaceae family
US8206724B2 (en) 2000-12-15 2012-06-26 Auburn University Method and compositions for vaccination comprising nucleic acid and/or polypeptide sequence of chlamydia
US20070149474A1 (en) 2000-12-15 2007-06-28 Auburn University Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of chlamydia
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
WO2002082091A2 (en) * 2001-04-09 2002-10-17 Allan Christian Shaw Method for identification of proteins from intracellular bacteria
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
EP1463520B1 (en) * 2001-12-12 2008-09-03 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia trachomatis
GB0203403D0 (en) * 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
EP2572707A3 (en) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
US7105171B2 (en) 2002-03-07 2006-09-12 The Regents Of The University Of California Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
DK1556477T3 (en) 2002-11-01 2017-10-23 Glaxosmithkline Biologicals Sa Process for drying
US7807802B2 (en) 2002-11-12 2010-10-05 Abbott Lab Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae
DE60332477D1 (de) 2002-11-15 2010-06-17 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004060396A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
PT1631264E (pt) 2003-06-02 2009-11-03 Novartis Vaccines & Diagnostic Composições imunogénicas à base de micropartículas biodegradáveis que compreendem um toxóide de difteria e do tétano
EP1689867A4 (en) * 2003-11-20 2007-08-22 Sanofi Pasteur Ltd IMMUNIZATION AGAINST CHLAMYDIA INFECTIONS
KR20060128894A (ko) * 2003-11-21 2006-12-14 사노피 파스퇴르 리미티드 클라미디아 감염에 대한 면역화
US20120027841A1 (en) 2004-01-07 2012-02-02 Biomedical Research Models, Inc. Novel mucosal vaccination approach for herpes simplex virus type-2
US7795419B2 (en) * 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
JP2008504292A (ja) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 免疫増強用の化合物
WO2006078318A2 (en) 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
EP2269636A3 (en) * 2004-10-25 2011-04-06 Statens Serum Institut Chlamydia trachomatis antigens for vaccine and diagnostic use
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
CN103372206A (zh) 2005-03-31 2013-10-30 葛兰素史密丝克莱恩生物有限公司 针对衣原体感染的疫苗
US8541007B2 (en) 2005-03-31 2013-09-24 Glaxosmithkline Biologicals S.A. Vaccines against chlamydial infection
US8133973B2 (en) 2005-05-12 2012-03-13 Novartis Vaccines And Diagnostics, S.R.L. Immunogenic compositions for Chlamydia trachomatis
WO2006128296A1 (en) * 2005-06-01 2006-12-07 Sanofi Pasteur Limited Pal-based chlamydia vaccine
WO2007030879A1 (en) * 2005-09-13 2007-03-22 Diatech Pty Ltd Diagnostic markers and uses therefor
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
DK2468300T3 (da) 2006-09-26 2018-01-29 Infectious Disease Res Inst Vaccinesammensætning indeholdende syntetisk adjuvant
EA015817B1 (ru) 2006-10-12 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция, содержащая адъювант в виде эмульсии "масло в воде"
PL2086582T3 (pl) 2006-10-12 2013-04-30 Glaxosmithkline Biologicals Sa Kompozycja zawierająca adiuwant w postaci emulsji typu olej w wodzie
CN100391544C (zh) * 2006-10-24 2008-06-04 天津医科大学总医院 沙眼衣原体e型dna疫苗及制备方法与用途
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
JP2010535504A (ja) * 2007-08-03 2010-11-25 プレジデント アンド フェロウズ オブ ハーバード カレッジ クラミジア抗原
AU2008299376B2 (en) 2007-09-12 2013-02-28 Glaxosmithkline Biologicals S.A. GAS57 mutant antigens and GAS57 antibodies
AU2008331800A1 (en) * 2007-12-03 2009-06-11 President And Fellows Of Harvard College Chlamydia antigens
PT2235046E (pt) 2007-12-21 2012-10-26 Novartis Ag Formas mutantes de estreptolisina o
SI2349520T1 (sl) 2008-10-27 2016-08-31 Glaxosmithkline Biologicals S.A. Postopek čiščenja za ogljikohidrat iz Streptococcus skupine A
AU2009333159A1 (en) * 2008-12-17 2011-08-04 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
WO2010078556A1 (en) 2009-01-05 2010-07-08 Epitogenesis Inc. Adjuvant compositions and methods of use
US8465751B2 (en) 2009-01-12 2013-06-18 Novartis Ag Cna—B domain antigens in vaccines against gram positive bacteria
WO2014022936A1 (en) * 2012-08-08 2014-02-13 The University Of British Columbia Chlamydia antigen compositions and uses thereof
EP2403526B1 (en) 2009-03-06 2019-05-15 GlaxoSmithKline Biologicals SA Chlamydia antigens
TWI494125B (zh) 2009-06-05 2015-08-01 Infectious Disease Res Inst 合成的葡萄吡喃糖基脂質佐劑
BR112012009014B8 (pt) 2009-09-30 2022-10-04 Novartis Ag Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica
ES2626416T3 (es) 2009-10-30 2017-07-25 Glaxosmithkline Biologicals Sa Purificación de sacáridos capsulares de Staphilococcus aureus de tipo 5 y de tipo 8
EP2575988A1 (en) 2010-05-28 2013-04-10 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
US20130315959A1 (en) 2010-12-24 2013-11-28 Novartis Ag Compounds
SG194083A1 (en) 2011-04-08 2013-11-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EP2723378A4 (en) 2011-06-24 2015-01-28 Epitogenesis Inc PHARMACEUTICAL COMPOSITIONS COMPRISING A COMBINATION OF VECTORS, VITAMINS, TANNINS AND FLAVONOIDS SELECTED AS ANTIGEN-SPECIFIC IMMUNOMODULATORS
WO2013038375A2 (en) 2011-09-14 2013-03-21 Novartis Ag Methods for making saccharide-protein glycoconjugates
JP2015501293A (ja) * 2011-09-30 2015-01-15 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア クラミジア抗原組成物およびその使用
CN104080479B (zh) 2011-11-07 2019-11-05 葛兰素史密丝克莱恩生物有限公司 包括spr0096和spr2021抗原的运载体分子
WO2013119856A1 (en) 2012-02-07 2013-08-15 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
JP6619648B2 (ja) 2012-05-16 2019-12-11 イミューン デザイン コーポレイション Ｈｓｖ−２のためのワクチン
KR20150021933A (ko) 2012-05-22 2015-03-03 노파르티스 아게 수막염구균 혈청군 x 포합체
JP6469585B2 (ja) 2013-01-07 2019-02-13 バイオメディカル リサーチ モデルズ， インコーポレイテッド 単純ヘルペスウイルス２型感染を処置するための治療用ワクチン
SG11201508092YA (en) 2013-04-18 2015-10-29 Immune Design Corp Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
MX2016008640A (es) 2013-12-31 2016-10-07 Infectious Disease Res Inst Formulaciones de vacuna de vial unico.
CA2973220A1 (en) 2014-01-16 2015-07-23 Mcmaster University Type iii secretion injectisome proteins for treatment and prevention of chlamydial infections
US11612664B2 (en) 2016-04-05 2023-03-28 Gsk Vaccines S.R.L. Immunogenic compositions
WO2017176076A1 (en) 2016-04-06 2017-10-12 Ewha University - Industry Collaboration Foundation A peptide with ability to penetrate cell membrane
ES2929054T3 (es) 2016-05-16 2022-11-24 Access To Advanced Health Inst Formulación que contiene un agonista de TLR y métodos de uso
BR112018073676B1 (pt) 2016-05-16 2023-10-03 University Of Virginia Patent Foundation Lipossomas peguilados e métodos de uso
IL315825A (en) 2016-06-01 2024-11-01 Access To Advanced Health Inst Nanoalum particles containing a fixing factor
BR112019026615B1 (pt) 2017-06-15 2022-08-02 Infectious Disease Research Institute Carreadores lipídicos nanoestruturados e emulsões estáveis e usos dos mesmos
AU2020283768A1 (en) 2019-05-25 2021-12-23 Access To Advanced Health Institute Composition and method for spray drying an adjuvant vaccine emulsion
CN111748021B (zh) * 2020-06-09 2021-09-07 温州医科大学 一种对沙眼衣原体momp具有结合亲和力的多肽及其应用
AU2021337493A1 (en) 2020-09-04 2023-05-18 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
EP4284832A1 (en) * 2021-01-29 2023-12-06 (INSERM) Institut National de la Santé et de la Recherche Médicale Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes
CN112960780B (zh) * 2021-03-03 2023-02-03 龙江环保集团股份有限公司 一种生物膜载体的预处理方法及生物法污水处理工艺

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2422956A1 (fr) 1978-04-13 1979-11-09 Pasteur Institut Procede de detection et de caracterisation d'un acide nucleique ou d'une sequence de celui-ci, et reactif enzymatique pour la mise en oeuvre de ce procede
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
FR2518755B1 (fr) 1981-12-23 1986-04-11 Pasteur Institut Sonde contenant un acide nucleique modifie et reconnaissable par des anticorps specifiques et utilisation de cette sonde pour detecter et caracteriser une sequence d'adn homologue
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
EP0192033B1 (en) * 1985-01-14 1996-09-25 Chiron Corporation Chlamydia major outer membrane protein
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
GB8709746D0 (en) * 1987-04-24 1987-05-28 Wenman W M Chlamydia vaccine
US5200051A (en) * 1988-11-14 1993-04-06 I-Stat Corporation Wholly microfabricated biosensors and process for the manufacture and use thereof
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2116269T3 (es) 1989-03-21 1998-07-16 Vical Inc Expresion de secuencias exogenas de polinucleotidos en un vertebrado.
WO1991006666A1 (en) 1989-11-06 1991-05-16 Cell Genesys, Inc. Production of proteins using homologous recombination
US5071962A (en) * 1990-05-31 1991-12-10 The United State Of America As Represented By The Department Of Health And Human Services Nucleotide, deduced amino acid sequence, isolation and purification of heat-shock chlamydial proteins
US6093558A (en) 1991-07-25 2000-07-25 Edge Biosystems, Inc. Binding protein of biologically active compositions to an adhesive formulation on a substrate
US5212062A (en) * 1991-09-06 1993-05-18 Kansas State University Method and composition to direct Chlamydia psittaci or Chlamydia trachomatis infection
CA2141450A1 (en) * 1992-07-31 1994-02-17 Maureen Laney Method for introducing defined sequences at the 3' end of polynucleotides
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
EP0698245A1 (en) 1993-05-14 1996-02-28 Mds Health Group Limited Electronic worksheet system for microbiology testing and reporting
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US5591580A (en) * 1994-03-31 1997-01-07 Johnson & Johnson Clinical Diagnostics, Inc. Method, test element and test kit for semi-quantitative detection of target nucleic acid
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
CA2761116A1 (en) 1995-04-27 1996-10-31 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
BR9814878A (pt) * 1997-11-21 2000-10-03 Genset Sa Sequência genÈmica e polipeptìdeos de chlamydia pneumoniae, fragmentos dos mesmos e usos dos mesmos, em particular para o diagnóstico, a prevenção e o tratamento de infecção
AU2017438534B2 (en) 2017-12-28 2020-05-21 Turntide Technologies Inc. Low-noise, high rotor pole switched reluctance motor

Also Published As

Publication number Publication date
WO1999028475A9 (en) 1999-08-26
EP2218730A1 (en) 2010-08-18
EP2218731A1 (en) 2010-08-18
KR20060109358A (ko) 2006-10-19
EP2228384A1 (en) 2010-09-15
AU1254599A (en) 1999-06-16
KR20060109516A (ko) 2006-10-20
KR20060109359A (ko) 2006-10-19
KR100735652B1 (ko) 2007-07-06
KR20060112695A (ko) 2006-11-01
KR100735651B1 (ko) 2007-07-06
EP2228385A1 (en) 2010-09-15
JP2009219494A (ja) 2009-10-01
AU754264B2 (en) 2002-11-07
KR100735653B1 (ko) 2007-07-06
WO1999028475A3 (en) 1999-11-18
CA2309228A1 (en) 1999-06-10
KR100769103B1 (ko) 2007-10-23
EP1032676A2 (en) 2000-09-06
EP2218732A1 (en) 2010-08-18
KR100769104B1 (ko) 2007-10-23
JP2002517179A (ja) 2002-06-18
CN1280619A (zh) 2001-01-17
KR20060112696A (ko) 2006-11-01
KR20010032581A (ko) 2001-04-25
WO1999028475A2 (en) 1999-06-10
KR100760221B1 (ko) 2007-10-30

Similar Documents

Publication Publication Date Title
BR9814912A (pt) Sequência genÈmica e polipeptìdeos de chlamydia trachomatis, fragmentos dos mesmos e usos dos mesmos, em particular para o diagnóstico, a prevenção e o tratamento de infecção
BR9814878A (pt) Sequência genÈmica e polipeptìdeos de chlamydia pneumoniae, fragmentos dos mesmos e usos dos mesmos, em particular para o diagnóstico, a prevenção e o tratamento de infecção
US20230123754A1 (en) RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
KR100735131B1 (ko) 핵산 증폭 방법
Lin et al. (A) BC excinuclease: the Escherichia coli nucleotide excision repair enzyme
ATE480625T1 (de) Äusseres membranpolypeptid von chlamydia pneumoniae sowie fragmente davon und deren verwendung, insbesondere zur diagnose, prävention und behandlung einer infektion
Tomcsányi et al. Processing enzyme ribonuclease E specifically cleaves RNA I: an inhibitor of primer formation in plasmid DNA synthesis
BR0006909A (pt) Sequências de nucleotìdeos que codificam o gene de opca
Soma et al. The Anticodon Loop is a Major Identity Determinant ofSaccharomyces cerevisiaetRNALeu
Bosi et al. Serratia marcescens nosocomial outbreak due to contamination of hexetidine solution
CA2289872A1 (en) Target-dependent reactions using structure-bridging oligonucleotides
BR0003943A (pt) Sequências de nucleotìdeo que codificam para o gene thre e processo para a produção enzimática de l-treonina usando bactérias corineforma
Miyaji-Yamaguchi et al. Coiled-coil structure-mediated dimerization of template activating factor-I is critical for its chromatin remodeling activity
BR0006915A (pt) Sequências de nucleotìdios para o gene tal
BR0014663A (pt) Moléculas de ácido nucléico para a detecção de bactérias e unidades filogenéticas de bactérias
BR0005804A (pt) Sequências de nucleotìdeos que codificam o genezwa1
KR100398558B1 (ko) 박테리아 플라스미드
CN109266728A (zh) 一种定位基因组dna上损伤和修饰位点的方法
CN109266628A (zh) 一种融合的TaqDNA聚合酶及其应用
Lyras et al. Transposable genetic elements and antibiotic resistance determinants from Clostridium perfringens and Clostridium difficile
Venner et al. Possible role of methylated DNA bases for the transcription of the genetic information
Das et al. Mechanism of 3′→ 5′ exonuclease associated with phage T5-induced DNA polymerase: processiveness and templete specificity
PT1631672E (pt) Vector de expressão circular destinado a aplicações na terapia genetica
Downard et al. Early RNAs in SP82-and SP01-infected Bacillus subtilis may be processed
Doctor et al. Isolation of 5S ribonucleic acid cistrons and tRNA cistrons from escherichiacoli

Legal Events

Date Code Title Description
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: GENSET (FR)

Free format text: A FIM DE ATENDER AO PEDIDO DE ALTERACAO DE NOME CONTIDO NA PETICAO NO 020050153908/RJ, DE 28/12/05, ESCLARECA DIVERGENCIA ENTRE O REQUERENTE E O TITULAR DO PEDIDO.

B25D Requested change of name of applicant approved

Owner name: SERONO GENETICS INSTITUTE S.A. (FR)

Free format text: ALTERADO DE: GENSET

B25G Requested change of headquarter approved

Owner name: SERONO GENETICS INSTITUTE S.A. (FR)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020050153908/RJ DE 28/12/2005.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA (ART. 8O COMBINADO COM ART. 13 DA LPI), NAO APRESENTA SUFICIENCIA DESCRITIVA (ART. 24 DA LPI) E AS REIVINDICACOES ESTAO INDEFINIDAS E NAO ESTAO FUNDAMENTADAS NO RELATORIO DESCRITIVO (ART. 25 DA LPI).

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time